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RESEARCH ARTICLE
Astrocytes infected with Chlamydia 
pneumoniae demonstrate altered expression 
and activity of secretases involved 
in the generation of β‑amyloid found 
in Alzheimer disease
Zein Al‑Atrache, Danielle B. Lopez, Susan T. Hingley and Denah M. Appelt* 
Abstract 
Background: Epidemiologic studies strongly suggest that the pathophysiology of late‑onset Alzheimer disease (AD) 
versus early‑onset AD has environmental rather than genetic causes, thus revealing potentially novel therapeutic 
targets to limit disease progression. Several studies supporting the “pathogen hypothesis” of AD demonstrate a strong 
association between pathogens and the production of β‑amyloid, the pathologic hallmark of AD. Although the mech‑
anism of pathogen‑induced neurodegeneration of AD remains unclear, astrocytes, a key player of the CNS innate 
immune response and producer/metabolizer of β‑amyloid, have been implicated. We hypothesized that Chlamydia 
pneumoniae infection of human astrocytes alters the expression of the amyloid precursor protein (APP)‑processing 
secretases, ADAM10, BACE1, and PSEN1, to promote β‑amyloid formation. Utilizing immunofluorescent microscopy, 
molecular, and biochemical approaches, these studies explore the role of an intracellular respiratory pathogen, 
Chlamydia pneumoniae, as an environmental trigger for AD pathology. Human astrocytoma cells in vitro were infected 
with Chlamydia pneumoniae over the course of 6–72 h. The gene and protein expression, as well as the enzymatic 
activity of non‑amyloidogenic (ADAM10), and pro‑amyloidogenic (BACE1 and PSEN1) secretases were qualitatively 
and quantitatively assessed. In addition, the formation of toxic amyloid products as an outcome of pro‑amyloidogenic 
APP processing was evaluated through various modalities.
Results: Chlamydia pneumoniae infection of human astrocytoma cells promoted the transcriptional upregulation of 
numerous genes implicated in host neuroinflammation, lipid homeostasis, microtubule function, and APP processing. 
Relative to that of uninfected astrocytes, BACE1 and PSEN1 protein levels were enhanced by nearly twofold at 48–72 h 
post‑Chlamydia pneumoniae infection. The processing of APP in Chlamydia pneumoniae-infected astrocytes favors the 
pro‑amyloidogenic pathway, as demonstrated by an increase in enzymatic activity of BACE1, while that of ADAM10 
was decreased. Fluorescence intensity of β‑amyloid and ELISA‑quantified levels of soluble‑APP by products revealed 
temporally similar increases, confirming a BACE1/PSEN1‑mediated processing of APP.
Conclusions: Our findings suggest that Chlamydia pneumoniae infection of human astrocytes promotes the pro‑
amyloidogenic pathway of APP processing through the upregulation of expression and activity of β‑secretase, 
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Background
Alzheimer Disease (AD) is a chronic, progressive neu-
rodegenerative illness regarded as the most common 
cause of dementia, which afflicts 46.8 million people 
worldwide—a number predicted to quadruple by the 
year 2050 [1]. AD also ranks among the top 10 causes of 
death in the US that can be neither prevented nor cured. 
Several investigations have aimed at deciphering etiolo-
gies that suggest the multiple causes or triggers of AD 
pathology [2, 3]. AD is diagnosed as one of two classifica-
tions: early-onset or familial AD, abbreviated EOAD or 
FAD, or late-onset or sporadic AD, abbreviated LOAD 
or SAD. Familial AD manifests symptoms at < 65 years of 
age. These cases are predominantly genetic and account 
for only 5% of all cases of AD. The majority of AD 
patients that present with symptoms at > 65 years of age 
are grouped into the category of late-onset AD. Numer-
ous genome-wide association studies have identified that 
certain risk-associated alleles are expressed differently in 
patients suffering from EOAD/FAD versus LOAD/SAD 
[4, 5]. However, the etiology of SAD pathology, unlike 
that of FAD, is considered multifactorial rather than 
strictly genetic.
In 1992, Hardy and Higgins [6] first introduced the 
amyloid cascade hypothesis to explain the etiology of 
AD, which proposes that beta-amyloid (Aβ) results from 
the enzymatic processing of amyloid precursor protein 
(APP). The amyloid cascade hypothesis claims that the 
neurotoxicity triggered by Aβ initiates related patho-
logic processes such as formation of extracellular senile 
plaques, which is one of the characteristic hallmarks of 
AD. Senile plaques are composed of oligomerized Aβ and 
are the pathologic findings in FAD and SAD brains. In its 
monomeric form, Aβ is a 39–42 amino acid peptide frag-
ment derived from the sequential cleavage of APP, a large, 
type I transmembrane protein. APP processing can occur 
in two pathways, the non-amyloidogenic pathway or the 
pro-amyloidogenic pathway. The initial APP-processing 
event is catalyzed predominantly by the α-secretase, a 
disintegrin and metalloproteinase-10 (ADAM10) in the 
non-amyloidogenic pathway [7], and the β-secretase, 
β-site APP cleaving enzyme 1 (BACE1), in the pro-amy-
loidogenic pathway [8, 9]. A second cleavage event is 
performed by a γ-secretase, a complex containing 4 subu-
nits: presenilin 1 or 2 (PSEN1 or PSEN2), as the catalytic 
subunit, nicastrin (NCSTN), anterior pharynx defensive 
phenotype 1 (APH1) and presenilin enhancer-2 (PEN2) 
[10, 11]. Cleavage of APP by ADAM10 or BACE1 releases 
the soluble amino terminal products, soluble APP-α 
(sAPPα) or soluble APP-β (sAPPβ), respectively, and car-
boxy terminal fragments, C83 and C99, respectively. In 
the non-amyloidogenic pathway, C83 is further cleaved 
by PSEN into the APP intracellular domain (AICD) and 
a p3 peptide, a non-toxic form of amyloid. Whereas in 
the amyloidogenic pathway, PSEN cleaves C99 into AICD 
and Aβ fragments, of which the 42 amino acid fragment 
(Aβ1-42) is considered the most neurotoxic [12]. Due to 
its hydrophobic characteristics, Aβ1-42 acts as a nidus for 
seeding additional Aβ peptide fragments, thereby facili-
tating large, extracellular aggregations of Aβ [13, 14].
In the context of SAD pathogenesis, the well-estab-
lished mutations of APP and PSEN that promote 
enhanced pro-amyloidogenic processing of APP in FAD 
are not implicated; rather, exogenous stimuli, such as 
environmental toxins or infectious pathogens that may 
alter their overall expression are implicated [15]. These 
exogenous stimuli trigger the activation of both neuronal 
and non-neuronal cells with subsequent release of pro-
inflammatory cytokines and activation of intracellular 
signaling pathways [16, 17]. As a result of these types of 
stressors, activated glial and neuronal cell models have 
demonstrated increased transcriptional expression, and/
or altered activity of ADAM10, BACE1, and PSEN1 
[18–20]. The etiology of neurodegeneration in SAD 
may therefore result from, at least in part, the effects of 
exogenous stimuli on the expression of APP-processing 
secretases.
One such stimulus that has garnered significant sup-
port as a potential trigger of SAD pathology is infection 
of the CNS by various pathogens. Several pathogens 
that have been implicated in SAD include cytomegalo-
virus, herpes simplex virus type 1, Borrelia burgdorferi, 
and Chlamydia pneumoniae (Cpn) [21, 22]. The role of 
Cpn in SAD pathology has been illustrated at both the 
epidemiologic and cellular levels. This relationship was 
first cited in the seminal study by Balin et  al. [23] that 
demonstrated that metabolically active Cpn was found 
by immunohistochemical, electron microscopic, and 
PCR techniques to be localized to areas of AD pathol-
ogy in 17 of 19 post-mortem AD brains compared to 1 
of 19 non-AD control brains. Another study validated the 
presence of viable Cpn in 80% of AD brains (versus 11.1% 
upregulated expression of γ‑secretase, and decreased activity of α‑secretase. These effects of astrocyte infection 
provide evidence for a direct link between Chlamydia pneumoniae and AD pathology.
Keywords: Alzheimer disease, Neuroinflammation, Neurodegeneration, Amyloid, Astrocytes, Secretase, BACE1, 
Chlamydia pneumoniae, Pathogens
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of age-matched controls) via multiple methods including 
in  situ hybridization and PCR analysis of Cpn-specific 
targets [24]. Additional evidence for a causal relation-
ship between Cpn and AD was demonstrated through 
intranasally inoculating the non-genetically manipulated 
BALB/c mouse with Cpn isolates from AD brains [25]. 
In that study, Aβ deposits associated with Cpn infec-
tion were found in brain areas that are typically affected 
in AD such as the hippocampus, the dentate gyrus and 
the amygdala. These plaques were surrounded by reactive 
astrocytes and, at times, encircled brain vasculature, sug-
gesting the presence of cerebral amyloid angiopathy.
Epidemiologic assessments of Cpn and other infectious 
burdens in control versus AD brains show a correlation 
between infection and AD [21, 22, 24]. This evidence 
supports the hypothesis that the chronic neuronal and 
glial cell dysfunction visualized in the brains of SAD 
patients may be derived from early-acquired CNS infec-
tion by Cpn and similar intracellular pathogens with the 
potential to persist over time and reactivate from latency 
or persistence.
An investigation into aberrant APP metabolism and 
Aβ accumulation in the setting of inflammation needs 
to include an analysis of the role of astrocytes, the most 
abundant glial cells in the CNS. A common observation 
among studies investigating Cpn in post-mortem AD 
brains [23] and brains of Cpn-inoculated BALB/c mice 
[25] was the colocalization of Cpn and GFAP-labeled 
astrocytes, suggesting astrogliosis in response to Cpn 
infection. It is interesting to note that glial activation in 
AD patients is not uncommon, as revealed by PET imag-
ing during the pre-symptomatic stages of AD, and is 
shown to correlate with the initial signs of Aβ accumu-
lation [26]. Animal models and in  vitro studies indicate 
that astrocytes respond to immune- and AD-associated 
triggers, such as TNF-α, IFN-γ, IL-1β, bacterial lipopoly-
saccharide and Aβ by releasing cytokines and modifying 
the expression and activity of APP processing enzymes, 
which in turn exacerbate neuroinflammatory and neu-
ropathological changes in the AD brain [19, 20, 27–30]. 
These findings support the contention that reactive 
astrocytes contribute to the neurodegeneration and loss 
of cognition observed in AD. Therefore, investigating 
the effect of infection by Cpn on the processing of APP 
by astrocytes is invaluable in modeling potential mecha-
nisms by which Cpn may trigger sporadic AD pathology, 
especially over time.
This study is aimed at investigating the effects of infec-
tion by Cpn on genes and the gene products involved in 
the processing of APP to produce Aβ, which is a major 
characteristic of AD pathology. By examining the effect 
of Cpn infection on validated pathways of astrocytic APP 
processing, this study provides evidence to support that 
AD pathology is recapitulated by infection with Cpn. This 
investigation explores how the expression and activity of 
APP-processing machinery, as defined by the amyloid 
cascade hypothesis, is altered as a result of Cpn infection 
of STTG1 human astrocytoma cells. The STTG1 human 
astrocytoma cell line has been suggested to be a valu-
able in  vitro model for AD and its experimental thera-
pies. This is due to STTG1’s heterozygous expression of 
the ApoE ε3/4 gene, its active participation in the pro-
inflammatory cascade, and ability to both synthesize and 
breakdown Aβ [31–34]. Therefore, this in vitro model of 
Cpn infection of the CNS not only enhances our under-
standing of pathologic AD mechanisms, but also brings 
to light new research avenues investigating “the pathogen 
hypothesis” for early diagnosis and treatment of sporadic 
AD.
Methods
Cell culture and infection with Chlamydia pneumoniae
The human astrocytoma cell line CCF-STTG1 (CRL-
1718) was obtained from American Type Culture Col-
lection (ATCC, Rockville, MD, USA). Cells were grown 
at 37 °C and 5%  CO2 as a monolayer in culture medium 
RPMI-1640 (ATCC, 10-2001) supplemented with 10% 
(v/v) fetal bovine serum (FBS) in culture flasks (Corn-
ing Cell Culture Treated Flasks). Cells were trypsinized 
(Thermofisher) and transferred to 12 or 6 well polysty-
rene plates  (Corning®  CellBIND®) in culture medium 
for the western blot and RT-PCR experiments. For the 
immunocytochemistry experiments, cells were grown 
on 18.5  mm glass coverslips (neuvitro, GG-18-1.5-pre) 
in sterile 12-well plates. For cell infection experiments, 
50% of conditioned growth media was removed and Cpn 
strain AR39 (ATCC, 52592) at MOI = 1 was added to 
5 × 104 to 1 × 105 cells/well. To minimize variability Cpn 
lot number was held constant throughout experiments 
and each time point for a given experiment  was inocu-
lated  on the same day. After centrifugation at 300×g 
for 30  min at RT, fresh growth media was added and 
cells were incubated for 6, 24, 48, and 72  h. Uninfected 
cells used as a negative control were processed in paral-
lel with Cpn-infected cells. This procedure describes the 
preparation for one biological replicate. Each timepoint 
was repeated to achieve samples in biological triplicate, 
for which each was run in at least technical triplicate for 
western blot analysis, ELISA, immunocytochemistry, and 
molecular studies. Additional information of sample sizes 
for each study is included in its respective figure legend.
Immunocytochemistry
Cells grown on sterile 18.5 mm glass coverslips were incu-
bated with the following primary antibodies: anti-Aβ1-42 
at 1:500 (Synaptic Systems, 218703); anti-ADAM 10 at 
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1:100 (abcam ab39180), anti-BACE1 at 1:500 (abcam, 
ab10716), anti-presenilin-1 at 1:500 (ProSci 4203). Sec-
ondary antibody was used at 1:500 (Alexa  Fluor® 594); 
FITC-conjugated chlamydial antibodies (Fitzgerald, 
61C75-A and 60C19) were used at 1:100 to visualize the 
infection. BD Perm/Wash™ was used to as the antibody 
diluent and cell wash buffer. Coverslips were mounted 
on glass slides using FLUORO-GEL II with DAPI (EMS, 
17985-50). Images were acquired using an Olympus 
FV1000 laser scanning confocal microscope with a 60×, 
1.4NA oil immersion objective lens and FluoView 1000 
software. For cell counts, images were acquired at 40× 
using the Nikon Eclipse 90i epi-fluorescence microscope.
Alzheimer disease RT‑PCR array
Cells were harvested and RNA was isolated in biological 
triplicate from Cpn infected and uninfected astrocytes at 
each timepoint post-infection. Purified RNA was reverse-
transcribed using  RT2 First Strand Kit (Qiagen, 330401). 
To ensure that the comparisons of gene expression were 
valid for each timepoint post-infection, an equal amount 
of RNA template from uninfected and Cpn-infected cells 
within each timepoint was used for cDNA synthesis. 
cDNA was used to profile 84 different genes included in 
the Human Alzheimer Disease  RT2 Profiler ™ PCR Array 
(Qiagen, PAHS-057ZC). Web-based PCR array data anal-
ysis software provided by Qiagen was used to collectively 
analyze raw  Ct values for each AD-related gene included 
in the assay [35]. Human β-actin was automatically cho-
sen by the analysis software as the housekeeping gene 
for standardization. Once each assay was normalized 
to β-actin, ΔCt values for each gene of interest in Cpn-
infected cells were compared to that of uninfected cells 
to obtain a fold change between gene of interest expres-
sion in uninfected cells and that of Cpn-infected cells for 
each timepoint. Statistical significance in fold change val-
ues were determined by the Qiagen online analysis soft-
ware, which uses a two-tailed student’s t test to compare 
gene expression in infected and uninfected samples. Sta-
tistically significant changes in expression of AD-related 
genes are listed in Additional File 1.
Western blot analysis
At the indicated timepoints post-infection, uninfected 
and Cpn-infected cells were lysed using 1 × RIPA lysis 
buffer (EMD Millipore, 20-188) supplemented with 1× 
protease inhibitor (Halt ™ Protease Inhibitor 100×, 
Thermo Scientific, 78430). Cell lysates were homoge-
nized mechanically with mortar and pestle and through 
ice-cold sonication before resolving on 4–20% pre-
cast polyacrylamide gels (Bio-Rad, Mini-PROTEAN® 
TGX™ gels, 456-1094) using 1× Tris/glycine/SDS 
running buffer (Bio-Rad, 161-0732). Gels were trans-
ferred onto nitrocellulose membrane  (iBlot® transfer 
stack, Life Technologies, IB3010-02). Membranes were 
then washed with wash buffer (Pierce ® Fast Western 
Blot Kit, Thermo Scientific, 35050) and labeled (24  h 
at 4  °C with gentle agitation) with primary antibodies 
diluted in antibody diluent (Pierce ® Fast Western Blot 
Kit, Thermo Scientific, 35050). The following primary 
antibodies were used: anti-ADAM10 at 1:400 (Santa 
Cruz Biotechnology, sc-48400), anti-BACE1 at 1:500 
(abcam, ab108394), anti-presenilin-1 at 1:500 (abcam, 
ab76083), anti-chlamydial antibody at 1:200 (Fitzger-
ald 10C27B), and to label the housekeeping protein 
of interest, anti-β-actin at 1:500 (Santa Cruz Biotech-
nology, sc-8432). The following secondary antibodies 
were used: goat anti-mouse and anti-rabbit conjugates 
at 1:500 (Bio-Rad, 170-5046 and 170-5047, respec-
tively).  SuperSignal® West Pico Chemiluminescent 
Substrate (Thermo Scientific, 34080) was then applied 
to the membranes and visualized using Bio-Rad Ver-
saDoc Imaging System 4000MP. Densitometry analy-
sis was conducted using FIJI software [36]. ADAM10, 
BACE1, and PSEN1 expression were assessed using the 
same samples, ensuring that the expression of each of 
these proteins could be accurately compared to each 
other. The expression of each protein of interest was 
quantified in 5–7 total samples. To determine statisti-
cal significance between protein levels derived from 
Cpn infected and uninfected cells, student’s t-test was 
conducted on the optical density values of each protein 
of interest normalized to that of β-actin as a loading 
control.
Quantitative analysis of Aβ1‑42 using immunofluorescence
Following immunolabeling with anti-Aβ1-42 as pre-
viously described, thirty 2  μm Z-stack images were 
acquired across 3 separate coverslips (approximately 
10 cells per coverslip) to ensure that representative 
populations of cells were captured and that the entire 
3-dimensional depth of labeled Aβ was included in the 
analysis. Using FIJI software [36], each Z-stack image 
was separated into its three individual channels; DAPI 
and FITC were removed at this point and analysis was 
performed on the TRITC channel. From each analyzed 
image, a single 2D composite image was resolved to 
represent the maximum fluorescence intensity of each 
pixel of each 0.2 μm slice. Threshold fluorescence level 
was defined to include all Aβ labeling within the area 
of the cell. Mean fluorescence intensity of Aβ fluores-
cence exceeding the threshold fluorescence level was 
obtained for each imaged cell and a student’s t-test was 
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conducted to determine statistical significance of Aβ1-42 
fluorescence intensity between infected and uninfected 
cells for 24, 48 and 72 h timepoints.
Quantitative analysis of soluble APPα and APPβ using 
Meso Scale Discovery (MSD) ELISA
At the indicated timepoints post-infection, condi-
tioned media from Cpn-infected and uninfected cells 
was removed and stored at − 80 °C. One milliliter of the 
conditioned media was thawed and concentrated using 
Eppendorf Vacufuge Plus at 45  °C. The MSD 96-well 
MULTI-SPOT sAPPα/sAPPβ assay was performed as 
directed by the manufacturer. Inter- and intra-assay %CV 
are listed in Additional File 2. Concentration readings of 
each individual sample (3 for each timepoint post-infec-
tion and infection status) of sAPPβ were divided by total 
sAPP (sAPPα + sAPPβ) to obtain a ratio of sAPPβ to total 
sAPP in the conditioned media of uninfected and Cpn-
infected treatment groups.
ADAM10 and BACE1 Activity Assay
AnaSpec Sensolyte 520 ADAM10 and BACE1 Activ-
ity Assay Kits (AS72226 and AS71144, respectively) 
were used as a fluorimetric method for determining 
ADAM10 and BACE1 activity in Cpn-infected and unin-
fected astrocytes. After 48 hpi, cells were counted, (data 
not shown in results) harvested and placed into pre-
chilled microcentrifuge tubes with pre-packed pestle for 
homogenization. Cells were washed with ice-cold PBS, 
and pelleted at 4  °C and 800×g for 10  min (4  samples 
for each treatment group). Mechanical and liquid nitro-
gen snap-freeze homogenization of fresh lysate allowed 
for retrieval of lysate without compromising enzymatic 
activity. Each enzyme assay was performed as directed 
by the manufacturer. Each sample was assayed in techni-
cal duplicate. Completed assays were loaded in a black, 
clear bottom plate and incubated at 37  °C for 1  h, then 
analyzed at Ex/Em 490/520 using a Fluoroskan Ascent 
FL microplate fluorometer. Background fluorescence of 
assay buffer was subtracted from final fluorescence meas-
urements and each final measurement was normalized 
based on the protein concentration as determined by 
BCA protein assay (Pierce, 23225).
Results
Chlamydia pneumoniae infects STTG1 human astrocytoma 
cells in vitro and is maintained through 72 h post infection
As visualized via confocal microscopy, the respiratory 
strain of Cpn, strain AR39, robustly infects STTG1 astro-
cytoma cells in  vitro and persists 72  h post-infection 
(hpi) (Fig.  1a). Percent infected cells, averaged across 
approximately 2000–2500 cells per timepoint, is shown 
in Fig. 1b. Percentages of infected cells were significantly 
different between 6 hpi versus 48 hpi and 72 hpi, 24 hpi 
versus 48  hpi and 72  hpi. This was determined through 
conducting a one-way ANOVA, demonstrating p < 0.05, 
and confirmed with Tukey HSD post hoc analysis. These 
Fig. 1 Chlamydia pneumoniae infects human astrocytes in vitro. STTG1 human astrocytes infected with Cpn strain AR39 at an MOI of 1 
demonstrated a diffuse punctate labeling of Cpn (green) from 6 to 72 hpi. Nuclei are labeled with DAPI (blue). Scale bar represents 20 μm (a). 
Infected versus uninfected cell counts were averaged across approximately N = 2000–2500 cells per timepoint and in biological triplicate across two 
independent infections. Numerical data is expressed as percent infected cells (b). Percentages of infected cells were significantly different between 
6 hpi versus 48 hpi and 72 hpi, 24 hpi versus 48 hpi and 72 hpi. Comparisons between populations were determined through one‑way ANOVA, 
where significance was defined as p < 0.05, and confirmed using Tukey HSD post hoc analysis. Error bars represent standard deviation of the mean
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data indicate that Cpn infects human astrocytoma cells 
within 6  hpi and appears to remain viable within these 
cells for at least 72 h, although the numbers of infected 
cells decrease after 24 hpi.
Chlamydia pneumoniae infection of human astrocytes 
alters the transcript expression of AD‑related genes
The human Alzheimer disease array revealed that 
Cpn infection at each timepoint post-infection altered 
the expression of several genes directly and indirectly 
involved with the development of AD pathology through 
APP processing and tau-related mechanisms. The fold 
changes in expression of the 84 AD-related genes in Cpn-
infected cells, compared to that of uninfected cells were 
standardized to β-actin. At 6, 24, 48, and 72 hpi, signifi-
cant changes in mRNA expression were observed in 40, 
33, 35, and 17 different genes, respectively. The remaining 
genes were not included in our analysis due to the lack 
of a significant difference in their expression (p > 0.05). 
The functional roles of these genes (Fig. 2a) in astrocytes 
are aberrant in multiple pathways of AD, including lipid 
metabolism (apolipoprotein E, APOE; lipoprotein lipase, 
LPL; lipoprotein receptor-related protein 1, LRP1), 
microtubule organization (microtubule-associated 
protein 2, MAP2; microtubule-associated protein tau, 
MAPT; glycogen synthase kinase 3β, GSK3B), and neuro-
inflammation (interleukin 1-α, IL1A) [29, 37–39]. More-
over, expression of genes associated with several of these 
pathways have been shown to be altered upon infection 
with Cpn [40–42]. An additional subset of genes included 
in this analysis encode the secretases involved in APP 
processing, as well as APP itself. The transcripts of APP, 
ADAM10, BACE1, and subunits of the γ-secretase com-
plex (PSEN1, PSEN2 APH1A and NCSTN) were sig-
nificantly upregulated (p < 0.05) in at least one of the 4 
investigated timepoints post-infection (Fig. 2b).
Cpn had its greatest effect on the transcriptional 
expression of APP-processing secretases 6, 24, and 
48 hpi. The altered gene expression observed as early as 
6 hpi indicates that early Cpn entry into the astrocyte host 
may act as a trigger for the expression of genes required 
for the processing of APP. The increase in expression 
of APP (33%), PSEN1 (39%), PSEN2 (17%) and APH1A 
(20%) observed in infected cells compared to uninfected 
cells was greatest at 6  hpi, while that of ADAM10 and 
BACE1 was most elevated at 24 and 48  hpi (approxi-
mately 30–50% over that of uninfected cells). PSEN1, 
PSEN2 and APH1A function in concert with nicastrin, 
which demonstrated the greatest increase in expression 
at 48  hpi (approximately 30% over that of uninfected 
cells), to form the γ-secretase complex (Fig. 2b).
Our data indicate that the greatest increase in expres-
sion of secretase genes occurred within the first 48 hpi, 
though apparently neither the pro- nor the non-amy-
loidogenic pathway is favored, since expression of both 
the α-secretase (ADAM10) and β-secretase (BACE1) 
were similarly increased. These findings suggest that 
Cpn infection may be enhancing the processing of APP 
through transcriptional upregulation of secretase-associ-
ated genes.
Chlamydia pneumoniae infection of astrocytes alters 
the expression of the APP processing secretases
To determine whether Cpn-induced transcriptional 
changes in ADAM10, BACE1, and PSEN1 expression 
were consistent at the protein level, these proteins were 
visualized in Cpn-infected cells via confocal immuno-
fluorescence. As ADAM10, BACE1, and PSEN1 proteins 
mature, they are recycled between the plasma and endo-
somal membranes [12], however, the antibodies used to 
visualize them in this study were chosen to be non-selec-
tive for intracellular and plasma membrane-localized 
populations. For example, BACE1’s C-terminal domain 
was targeted, which will detect BACE as it is recycled to 
and from endosomes and the plasma membrane or as it 
is shuttled through the late endosome/lysosome pathway.
Overall, the total fluorescence of each labeled protein 
in Cpn-infected cells showed very subtle differences at 
each timepoint post-infection compared to that of unin-
fected cells. ADAM10 labeling was not qualitatively dif-
ferent in Cpn-infected versus uninfected cells; BACE1 
and PSEN1 labeling did show noticeable variations 
post-Cpn infection (Fig. 3). In our studies, the pattern of 
BACE1 labeling differed between uninfected and infected 
astrocytes, potentially representing localization to cellu-
lar membranes in Cpn-infected cells, though the inten-
sity of BACE1 labeling appeared unchanged. Labeling of 
PSEN1, on the other hand, did appear increased in Cpn-
infected relative to uninfected astrocytes.
Chlamydia pneumoniae infection of astrocytes increases 
the protein expression of secretases involved in APP 
processing
To examine Cpn’s regulatory dynamics on the non-amy-
loidogenic processing pathway, total cell lysates from Cpn 
infected and uninfected cells at 24, 48, and 72 hpi were 
harvested for western blot analysis to semi-quantitatively 
assess the expression of ADAM10 (α-secretase), BACE1 
(β-secretase) and PSEN1 (a component of the γ-secretase 
complex). Densitometry histograms of fold change of 
ADAM10, BACE1 or PSEN1 protein levels in Cpn-
infected cells represent the average change in protein 
levels across 5–7 replicates per time point, normalized 
to that of β-actin within each sample and shown relative 
to the amount of the respective protein present in unin-
fected cells for each timepoint (Fig. 4).
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The ADAM10 antibody used for western blots detected 
an immature, proenzyme form of ADAM10 (~ 90  kDa), 
the initiating enzyme for this pathway. Full length 
ADAM10 requires posttranslational modifications to 
be active, therefore the ADAM10 labeling presented in 
these analyses detects inactive enzyme [12]. Compared 
to that of uninfected samples, Cpn-infected astrocyte cell 
lysates showed a statistically significant 1.4 fold increase 
in ADAM10 protein levels (p < 0.05) at 24  hpi, but no 
significant changes were measured at other timepoints, 
although the trend at 72 hpi indicated increased protein 
levels in infected cells at this timepoint (Fig. 4).
The protein expression of BACE1 was assessed to 
determine Cpn’s effect on the pro-amyloidogenic pro-
cessing of APP. The BACE1 labeling observed at approxi-
mately 75  kDa corresponds to the mature form of the 
protein. Mature BACE1 protein levels detected in Cpn-
infected versus uninfected cell lysates significantly 
increased by 1.9 and 2.2 fold after 48 and 72 hpi, respec-
tively, over that of uninfected cells (Fig.  4). These data 
Fig. 2 Chlamydia pneumoniae infection of human astrocytes alters the transcript expression of AD‑related genes. Gene transcripts from 
Cpn‑infected and uninfected cells analyzed at all four timepoints post‑infection revealed significant fold changes in genes closely related to AD 
pathology. The fold changes of fourteen genes implicated in known pathways of AD pathology are presented in a. Histograms of fold changes of 
these AD‑associated genes are presented in b. All expression data was normalized to β‑actin and Cpn‑infected and uninfected cDNA samples were 
repeated in biological (N = 3) and technical triplicate for each timepoint. Asterisk indicates p < 0.05. ADAM10, A disintegrin and metalloproteinase 
10; APH1A, anterior pharynx defective protein 1A; APOE, apolipoprotein E; APP, amyloid precursor protein; BACE1, βAPP‑cleaving enzyme 1; 
GSK3B, glucogen synthase kinase 3‑β; IL1A, interleukin 1α; LPL, lipoprotein lipase; lipoprotein receptor‑related protein 1, LRP1; MAP2, microtubule 
associated protein 2; MAPT, microtubule associated protein tau; NCSTN, nicastrin; PSEN1, presenilin‑1, PSEN2, presenilin‑2
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suggest that Cpn infection results in a more extensive 
increase in protein levels of intracellular BACE1 relative 
to ADAM10, which may promote a pro-amyloidogenic 
rather than a non-amyloidogenic processing pathway of 
APP. Additionally, the increase in BACE1 protein expres-
sion observed with these studies does not seem transient; 
as time of infection progresses, BACE1 protein levels 
continued to increase throughout the 72 h of infection.
Active PSEN1 is localized to numerous subcellular 
compartments of the cell [43]. The antibody used for 
PSEN1 labeling via western blot analysis did not detect 
intracellular levels of full length PSEN1, which appears 
at 50 kDa, but rather a 20 kDa band, indicating proteo-
lytically cleaved, and therefore active, carboxy terminal 
fragment (CTF) of PSEN1. At all timepoints tested (24, 
48, and 72  hpi), PSEN1 CTF protein levels detected in 
Cpn-infected cell lysates were significantly increased 
over those of uninfected controls (p < 0.05) (Fig.  4). 
Corroborating the observations made via confocal 
immunofluorescence, these western blot results provide 
additional evidence for the role of Cpn in facilitating the 
accumulation of potentially active PSEN1.
Fluorescence intensity of Aβ1‑42 is increased in Chlamydia 
pneumoniae infected astrocytes
Approximately 30 Z-images of uninfected and Cpn-
infected cells were acquired for each timepoint and 
resolved into a single, 2D representation of the maximum 
Aβ1-42 fluorescence intensity of each 0.2 μm optical sec-
tion (Fig. 5a). Aβ1-42 was localized within all cells, regard-
less of treatment group, indicating constitutively active 
APP-processing. Mean Aβ1-42 fluorescence intensity in 
Cpn-infected astrocytes, relative to that of uninfected 
cells, did not differ significantly at 24 hpi; however, it was 
elevated in infected cells at 48 and 72 hpi relative to unin-
fected cells from the same timepoint (Fig. 5b), indicating 
an increase in pro-amyloidogenic processing of APP at 
later times of infection.
Fig. 3 Chlamydia pneumoniae infection of astrocytes alters labeling of secretases. Astrocytes infected with Cpn from 6 to 72 hpi were double 
labeled for Cpn (green) and secretases ADAM10, BACE1 or PSEN1 C‑terminal fragment (red). 10–15 cells per biological replicate were imaged against 
an equal number of uninfected control cells. Cells were visualized using laser scanning confocal microscopy, maintaining the voltage settings of 
each color channel identical across biological replicates. DAPI was used to visualize the nucleus. Representative images are included this figure. 
Scale bar represents 20 μm
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Chlamydia pneumoniae infection alters the activity 
of ADAM10 and BACE1 in initiating cleavage of APP
To study Cpn’s effect on ADAM10 and BACE1 activi-
ties in the initial cleavage of APP, MSD ELISA was used 
to quantify the concentration of soluble APPα (sAPPα) 
and soluble APPβ (sAPPβ) in the conditioned media of 
uninfected and Cpn-infected cells. Corroborating the sig-
nificantly increased intracellular Aβ1-42 at 48 and 72 hpi, 
we observed a significant increase in the ratio of sAPPβ/
total sAPP, expressed as a percentage (Fig. 6), at 48 and 
72  hpi in Cpn-infected cells when compared to that of 
uninfected cells (p < 0.05). The levels of sAPPβ relative to 
total sAPP released by uninfected cells did not vary sig-
nificantly between time points, suggesting a regulated 
balance of APP processing by ADAM10 and BACE1.
Chlamydia pneumoniae infection of astrocytes results 
in increased activity of BACE1 and decreased activity 
of ADAM10
The enzymatic activity of ADAM10 and BACE1 is con-
tingent upon post-translational modifications that affect 
each enzyme’s trafficking to the optimal subcellular com-
partments for APP cleavage [12, 44]. To determine if 
Cpn-induced altered expression of ADAM10 and BACE1 
at the protein level correlated to their altered enzymatic 
activity, fluorimetric FRET-based enzyme assays were 
conducted on whole cell lysate of uninfected and Cpn-
infected cells. Compared to that of uninfected cells, the 
concentration of ADAM10-cleaved, fluorescent substrate 
in Cpn-infected cell lysate at 48 hpi exhibited an overall 
decreased trend in ADAM10 activity (Fig. 7). In contrast, 
the concentration of BACE1-cleaved, fluorescent sub-
strate generated by Cpn-infected cell lysate 48  hpi was 
significantly greater than that of uninfected cell lysate 
(p < 0.05), indicating an overall greater activity of BACE1 
in these samples (Fig. 7).
Discussion
By investigating Cpn’s effect on the transcription and 
localization of APP-processing secretases, this study 
is the first to propose a mechanism by which a respira-
tory strain of Cpn alters APP processing in an astrocyte 
host. Balin et al. [23] identified the Cpn pathogen within 
neurons, microglia and astroglia of AD brain tissue. Fol-
lowing this initial study, numerous groups have explored 
the roles of astrocytes as hosts for Cpn [45–47]. While 
our data indicate that Cpn clearly infects astrocytes, the 
percent of astrocytes that were infected decreased over 
time. The life cycle of Cpn is complex and involves tran-
sitioning from an infectious, elementary body (EB) to a 
metabolically active, reticulate body (RB) form of growth 
before converting back to an EB that can be released to 
infect new cells. Under conditions of stress, Cpn can 
persist as viable but noninfectious aberrant bodies (AB), 
which can revert back to RBs when conditions favor 
active multiplication [48]. It is possible that if cell divi-
sion occurs more rapidly than Cpn can complete its life 
cycle and spread to a new host cell, then the number of 
Fig. 4 Protein expression of ADAM10, BACE1 and PSEN1 in Chlamydia pneumoniae‑infected and uninfected astrocytes. Whole cell lysate was 
harvested from Cpn‑infected and uninfected astrocytoma cells, resolved via SDS‑PAGE gel electrophoresis, and labeled for secretase proteins. Fold 
change represents densitometry analysis for protein levels of full‑length ADAM10, BACE1 and PSEN1 C‑terminal fragment in Cpn‑infected cells 
compared to that of uninfected cells at the same timepoint post infection. All densitometry values were normalized to that of β‑actin for each 
biological replicate (N = 5–7). Statistical analysis was conducted using student’s T‑test of fold change within each timepoint (asterisk indicates 
p < 0.05). Error bars represent standard error of the mean
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infected cells relative to uninfected cells will decrease 
over time. Alternatively, it is possible that Cpn forms ABs 
in astrocytes, which would not subsequently spread to 
astrocytes arising from division of uninfected cells. This 
also could account for the decrease in % infected astro-
cytes observed over time.
In this study, we report that having gained access into 
the astrocyte host, Cpn promotes significant dysregula-
tion of important AD-related genes directly involved with 
APP processing, pathologic lipid trafficking and micro-
tubule dysfunction. While physiologically abnormal and 
potentially harmful for a mammalian host, the altered 
Fig. 5 Fluorescence intensity of Aβ1‑42 is increased in Chlamydia pneumoniae‑infected astrocytes. Aβ1‑42 (red) and Cpn (green) were visualized by 
laser scanning, confocal microscopy (a). To analyze the Z‑images using FIJI software, a defined threshold subtraction was applied equally to each 
image to determine Aβ1‑42 fluorescence intensity (b); mean fluorescence intensity was calculated for infected and uninfected astrocytes at 24, 48 
and 72 hpi. Cells (N = 25–30) were analyzed across three biological replicates to reliably conduct a student’s t‑test on the fluorescence intensities of 
Aβ1‑2 in uninfected and Cpn‑infected cells. Error bars represent standard error of the mean. Asterisk represents p < 0.05
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expression of these genes may have distinct benefits for 
Cpn infecting target cells. For example, Cpn infection of 
endothelial cells, monocytes, and macrophages has been 
shown to alter the expression of lipid homeostasis genes 
[40, 42, 49] and allow the acquisition and utilization of 
host lipids by Cpn as the pathogen is unable to synthesize 
them de novo [50]. The increased mRNA levels of apoli-
poprotien E (ApoE) and lipoprotein lipase (LPL) observed 
in Cpn-infected astrocytes relative to uninfected cells at 
6 hpi may therefore be necessary to allow Cpn to initiate 
infection within the astrocyte host. In addition, APOE 
has been shown to play a role in the attachment and 
internalization of several intracellular pathogens, includ-
ing Cpn [51–53]. The observed early increase in ApoE 
transcript expression may enhance internalization of Cpn 
EB’s during infection. Cpn-induced changes in host gene 
expression presumably evolved to enhance the infectiv-
ity of the bacterium, while potential AD-related patho-
logic effects associated with altered host gene expression 
would be an indirect consequence of Cpn infection.
It is conceivable that the initial increase in transcrip-
tional ApoE expression has a direct impact on expres-
sion of APP. A recent study noted that the binding of glial 
ApoE to its receptors enhances the transcription of APP 
through activating the transcription factor activator pro-
tein-1 (AP-1) and its associated family of downstream 
effectors [54], the consequence of which may account for 
the 30% increase in APP transcription seen at 6 hpi. Fur-
thermore, infection of endothelial cells by Cpn activates 
AP-1, and activation of this transcription factor regu-
lates Cpn-induced inflammation [55]. If a similar sce-
nario occurs in Cpn-infected astrocytes, AP-1 may play 
a role in mediating Cpn-triggered neuroinflammation as 
well as modulating levels of APP, and indirectly, Aβ lev-
els. Data presented here indicate that Cpn stimulated 
transcription of the proinflammatory cytokine interleu-
kin 1α (IL1α), suggesting that infection of astrocytes by 
Cpn promoted an inflammatory response. Moreover, a 
Fig. 6 Quantification of sAPPβ/total sAPP in media of uninfected 
and Chlamydia pneumoniae infected astrocytes using MSD ELISA. 
Conditioned media of uninfected and Cpn‑infected cells at each 
timepoint post‑infection was collected, concentrated, and assayed 
in equal volumes for sAPPβ and sAPPα levels. Standard curves of 
known concentrations of sAPPβ and sAPPα was used to determine 
the concentration of these individual Aβ species. Conditioned media 
was obtained from three biological replicates and the assay was 
conducted in technical triplicate. Student’s t‑test was calculated 
using the average sAPPβ/total sAPP ratio of Cpn‑infected conditioned 
media compared to that of uninfected conditioned media. Asterisk 
represents p < 0.05
Fig. 7 BACE1 activity is increased and ADAM10 activity is decreased in Chlamydia pneumoniae infected astrocytes. FRET‑based assays were used to 
quantify the activity of ADAM10 and BACE1 enzyme activity generated by Cpn‑infected and uninfected cell lysates at 48 hpi. Fluorescence of the 
5‑FAM or HiLyte Fluor 488 dyes conjugated to ADAM10 or BACE1‑specific substrates was detected as a result of cleavage by the respective enzymes 
and compared back to fluorescence intensity of known dye concentrations. The quantified dye concentration from ADAM10 and BACE1 fluorescent 
substrate cleavage from (N = 4) biological replicates of Cpn‑infected and uninfected cell lysates is presented as an average in the histograms. Error 
bars represent standard error of the mean. Asterisk represents p < 0.05
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study by Lim et al. [41] reported that Cpn can activate an 
inflammatory response in monocytes, which, if occurring 
in microglial cells of the central nervous system, would 
reactivate nearby astrocytes. It is likely that Cpn infec-
tion in the human brain would trigger an inflammatory 
response that would exacerbate neurodegeneration asso-
ciated with AD.
In this study, it is shown that Cpn infection of astro-
cytes decreased levels of microtubule-associated pro-
tein tau (MAPT) and microtubule-associated protein 2 
(MAP2) mRNA, and increased that of glycogen synthase 
kinase 3-β (GSK3β), a kinase that can phosphorylate tau. 
A decrease in tau protein would destabilize host microtu-
bules, whereas an increase in tau phosphorylation would 
subsequently decrease tau binding to, and stabilization 
of, microtubules [56]. An increase in GSK3β activity in 
Cpn-infected astrocytes could potentially enhance the 
formation of neurofibrillary tangles, which are composed 
of hyperphosphorylated tau proteins, thereby contribut-
ing to tau-mediated pathology that occurs in AD.
Changes in the expression of ADAM10, BACE1, and 
PSEN1 in Cpn-infected astrocytes will directly affect 
the processing of APP. In the present study, we observed 
significant increases in the expression of ADAM10 
mRNA by 40–50% in Cpn-infected astrocytes relative 
to uninfected cells, as well an increase in the full length 
ADAM10 protein. However, it is important to note that 
the ADAM10 proenzyme needs posttranslational pro-
cessing to be active and thus protein levels determined 
in this study may not accurately represent enzymatically 
active ADAM10 [7, 12]. In fact, ADAM10 protein levels 
tended to increase with Cpn infection while enzymatic 
activity was diminished at 48  hpi. These data suggest 
that posttranslational modification and/or trafficking of 
ADAM10 may differ in infected and uninfected astro-
cytes, resulting in decreased α-secretase-mediated non-
amyloidogenic cleavage of APP in Cpn-infected cells.
Protein levels of both BACE1 and PSEN1 in Cpn-
infected astrocytes progressively increased from 24 to 
72 hpi relative to uninfected cells. Relative mRNA levels 
were greatest at 48 hpi for BACE1 and 6 hpi for PSEN1, 
indicating that the proteins persisted after transcription 
of these genes returned to levels consistent with that seen 
in uninfected astrocytes. The progressive increase in the 
amount of BACE1 and PSEN1 in Cpn-infected astrocytes 
over time paralleled the observation that Aβ1-42 labeling 
was greatest in infected cells at 48 and 72 hpi. It has been 
shown that in the presence of Aβ1-42, BACE1 activity is 
elevated because of impaired lysosomal degradation of 
BACE1, indicating that increased pro-amyloidogenic 
processing of APP favors persistence of this β-secretase 
[57, 58]. This positive feedback between Aβ1-42 and 
BACE1 levels may have occurred in our Cpn-infected 
astrocytes. Furthermore, it has been shown that low-
density lipoprotein receptor-related protein 1 (LRP1) 
regulates BACE1 expression and activity by directing the 
β-secretase to lysosomes for degradation, while a loss of 
LRP1 expression correlates with an increase in BACE1 
activity [59]. Thus the decreased transcription of LRP1 
observed in Cpn-infected astrocytes may contribute to 
the increase in BACE1 expression and activity observed 
in infected astrocytes.
The lack of a significant increase in the fluorescence 
intensity of Aβ1-42 at 24 hpi suggests that prior to 24 hpi, 
the pro-amyloidogenic pathway has not been upregu-
lated. If the increase in APP mRNA observed in Cpn-
infected astrocytes at 6  hpi signals an increase in APP 
protein, then the surplus APP within the cell is pro-
cessed by the non-amyloidogenic pathway at an early 
time of infection. However, at 48 to 72  hpi, the signifi-
cant increase in Aβ1-42 fluorescence labeling in infected 
astrocytes suggests that in the presence of Cpn, either 
pro-amyloidogenic processing of APP is stimulated and/
or there is decreased clearance of toxic, intracellular 
Aβ products. The increased protein concentration of 
BACE1 and PSEN1 present in infected astrocytes at 48 
and 72  hpi supports the conclusion that increased pro-
cessing of APP may be responsible for the greater intra-
cellular accumulation of Aβ1-42, however doesn’t rule out 
the possibility of decreased clearance of Aβ. Our data 
indicating that the ratio of sAPPβ per total sAPP (sAPPα 
and sAPPβ) was significantly increased in Cpn-infected 
astrocytes at 48 and 72 hpi further supports the conclu-
sion that APP processing favored the pro-amyloidogenic 
pathway as the infection progressed. These results could 
be explained by either an increase in BACE1-mediated 
cleavage and/or a decrease in ADAM10-mediated cleav-
age of APP. Interestingly, enzyme activity assays for 
BACE1 and ADAM10 indicated that at 48  hpi, enzy-
matic activity in Cpn-infected astrocytes was increased 
for BACE1 and decreased for ADAM10 relative to that 
measured in uninfected cells.
Our study supports the postulate that the mechanism 
by which Cpn induces AD pathology centers on the abil-
ity of the pathogen in astrocytes to temporally alter the 
expression and activity of the α- and β-secretases, and 
thereby alter the balance between the non- and pro-amy-
loidogenic APP processing pathways that occurs in unin-
fected cells. This study is the first to quantify the altered 
regulation of the predominant α, β-, and γ-secretases in 
the CNS, namely ADAM10, BACE1, and PSEN1, respec-
tively, and Aβ1-42 in human astrocytes infected with Cpn. 
We have demonstrated that Cpn infection causes a sig-
nificant increase in the amyloidogenic processing of 
APP, which correlates with increased protein levels and 
activity of the rate-limiting enzyme, BACE1. Whether 
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through upregulating the transcriptional or post-tran-
scriptional expression of BACE1 and the subunits of 
γ-secretase and/or simultaneously disrupting normal 
secretase trafficking, severe downstream effects on the 
CNS may result secondary to Cpn infection. Over time, 
Cpn-induced astrocyte activation culminating in neuro-
inflammation, altered APP processing favoring the amy-
loidogenic pathway, dysregulation of tau expression and 
function, and eventually neuronal death causes chronic, 
irreversible damage, resulting in pathology similar to that 
found in the CNS of AD patients.
Future directions
This investigation explores a potential Cpn-induced 
mechanism for Aβ formation by focusing on the path-
way of APP processing by proamyloidogenic secretases, 
thereby identifying a putative early event triggering 
AD-associated pathology. While this study is the first 
to model a stable, Chlamydia pneumoniae-infection of 
human astrocytes in vitro and investigate its downstream 
effects on AD-related secretases, numerous additional 
studies can be conducted to further support our conclu-
sions. The STTG1 human astrocytoma cell line has been 
used as a viable astrocyte model for AD [31–34]. Con-
sidering Cpn has been found in multiple areas of human 
cortex and vasculature as reported by Balin et  al. [23], 
reproducing Cpn infection in additional cell types such 
as other astrocyte and glial cell lines, neuronal cells, and 
endothelial cells may provide a more thorough under-
standing of in  vivo Cpn infection. Reversing the patho-
logic effects of Cpn infection with anti-microbial or 
anti-inflammatory medication may provide a viable ther-
apeutic option for AD. In support of this, Hammond et al. 
[60] demonstrated decreased cerebral Aβ load in BALB/c 
mice inoculated with Cpn and subsequently treated with 
Moxifloxacin. Recent studies implicating pathogens in 
AD, including this current study, suggest that eliminating 
infectious triggers for AD pathology may be beneficial as 
a therapeutic target for preventing the initiation or pro-
gression of AD (Additional file 2).
Conclusions
This study examines the effect of Chlamydia pneumoniae 
infection on astrocytes, a major cell type in the CNS that 
plays an important role in establishing a state of neuro-
inflammation and neurodegeneration in the brain. Spe-
cifically, the data suggest that infection by Chlamydia 
pneumoniae promotes the pro-amyloidogenic pathway 
of APP processing by manipulating the expression and 
activity of the major secretases involved in generating 
toxic and nontoxic fragments of APP. Pro-inflammatory 
processes in the brain, and environmental stimuli that 
favor the pro-amyloidogenic pathway of APP processing, 
are emerging as potential triggers for the pathology asso-
ciated with AD. We present evidence of an association 
between AD pathology and infection with Chlamydia 
pneumoniae, supporting the concept of an infectious eti-
ology as a candidate to be considered in the pathogen-
esis of late onset AD. Furthermore, this study presents a 
potential target for preventing or slowing the progression 
of this neurodegenerative disease.
Additional files
Additional file 1: AD array tables. Table S1. AD‑associated genes whose 
expression was significantly altered in Cpn‑infected cells relative to 
uninfected cells at 6 hpi. Table S2. AD‑associated genes whose expression 
was significantly altered in Cpn‑infected cells relative to uninfected cells at 
24 hpi. Table S3. AD‑associated genes whose expression was signifi‑
cantly altered in Cpn‑infected cells relative to uninfected cells at 48 hpi. 
Table S4. AD‑associated genes whose expression was significantly altered 
in Cpn‑infected cells relative to uninfected cells at 72 hpi. Description: 
These tables list the Alzheimer‑associated genes whose expression in Cpn‑
infected cells significantly differed from that of uninfected cells. The genes 
examined were included in the Human Alzheimer Disease  RT2 Profiler ™ PCR Array (Qiagen, PAHS‑057ZC) that profiled 84 different Alzheimer‑
associated genes.
Additional file 2: MSD ELISA %CV values. Table S1. Percent CV for 
soluble APPα. Table S2. Percent CV for soluble APPβ. Description: These 
tables list intra‑ and inter‑ELISA % coefficient of variation (CV) for the data 
generated by MSD ELISA.
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